Reduction of HbA1c with dulaglutide in type 2 diabetes (T2D) patients negative, low positive or high positive for GAD antibodies (GADA): a post hoc analysis of AWARD-2,-4 and-5

被引：0

作者：

Pozzilli, P. ^{[1
]}

Leslie, R. D. ^{[2
]}

Peters, A. ^{[3
]}

Buzzetti, R. ^{[4
]}

Shankar, S. S. ^{[5
]}

Milicevic, Z. ^{[6
]}

Pavo, I. ^{[6
]}

Lebrec, J. ^{[7
]}

Martin, S. ^{[5
]}

Schloot, N. ^{[7
]}

机构：

[1] Univ Campus Biomed, Dept Endocrinol & Diabet, Rome, Italy

[2] Blizard Inst, London, England

[3] USC, Keck Sch Med, Dept Endocrinol & Diabet, Los Angeles, CA USA

[4] Sapienza Univ Rome, Dept Expt Med, Rome, Italy

[5] Eli Lilly & Co, Indianapolis, IN 46285 USA

[6] Eli Lilly & Co, Vienna, Austria

[7] Lilly Deutschland GmbH, Bad Homburg, Germany

来源：

DIABETOLOGIA | 2017年 / 60卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

145

引用

页码：S68 / S68

页数：1

共 50 条

[41] Efficacy of once-weekly dulaglutide on HbA1c reduction in East Asian patients with T2DM: subgroup analysis according to potential influencing factors
Peng, Yongde
Zhang, Bin
Hou, Jianing
DIABETES-METABOLISM RESEARCH AND REVIEWS, 2019, 35
[42] PEMAFIBRATE IMPROVED POSTPRANDIAL TG, REML-C AND APOB48 IN PATIENTS WITH TYPE 2 DIABETES (T2D) AND HYPERTRIGLYCERIDEMIA: A POST-HOC ANALYSIS OF THE PHASE 3 CLINICAL TRIAL
Arai, H.
Yamashita, S.
Yokote, K.
Araki, E.
Hounslow, N.
Ikeda, K.
Nojima, T.
Suganami, H.
Ishibashi, S.
ATHEROSCLEROSIS, 2022, 355 : E146 - E146
[43] Treatment Effects of Once-Weekly Dulaglutide vs. Insulin Glargine in Patients with Different Baseline Glycemic Patterns (Based on High/Low Fasting or High/Low Postprandial Glucose)-A Post-Hoc Analysis of the AWARD-2 Clinical Trial
Giorgino, Francesco
Yu, Maria
Haupt, Axel
Milicevic, Zvonko
Garcia-Perez, Luis-Emilio
DIABETES, 2018, 67
[44] Efficacy and Safety of Dulaglutide Monotherapy Compared to Glimepiride in Oral Antihyperglycemic Medication-Naive Chinese patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN1
Li, Yi Ming
Zhang, Li Hui
Li, Xue Jun
Zhang, Bin
Hou, Jia Ning
Tong, Nan Wei
DIABETES THERAPY, 2020, 11 (05) : 1077 - 1090
[45] Efficacy and safety of subgroup analysis stratified by baseline HbA1c in a Japanese phase 3 study of dulaglutide 0.75 mg compared with insulin glargine in patients with type 2 diabetes
Kaneko, Shizuka
Oura, Tomonori
Matsui, Akiko
Shingaki, Tomotaka
Takeuchi, Masakazu
ENDOCRINE JOURNAL, 2017, 64 (12) : 1165 - 1172
[46] Exploration of the Relationship of Reduction in HbA1c and Body Weight by Dapagliflozin in Patients With T2DM: Pooled Analysis of 5 Clinical Trials
Hardy, Elise
Salsali, Afshin
Wessman, Catrin
Wei, Li
Mansfield, Traci
Parikh, Shamik
DIABETES, 2012, 61 : A252 - A252
[47] Durable Improvement in HbA1c in Youth-Onset T2D-A Post Hoc Analysis of the DINAMO Trial of Empagliflozin and Linagliptin vs. Placebo
Laffel, Lori M.
Danne, Thomas
Tamborlane, William V.
Klingensmith, Georgeanna J.
Neubacher, Dietmar
Tartakovsky, Igor
Marquard, Jan
Zeitler, Philip
Willi, Steven M.
DIABETES, 2023, 72
[48] A Target HbA1c Between 7 and 7.7% Reduces Microvascular and Macrovascular Events in T2D Regardless of Duration of Diabetes: a Meta-Analysis of Randomized Controlled Trials
Sinha, Binayak
Ghosal, Samit
DIABETES THERAPY, 2021, 12 (06) : 1661 - 1676
[49] Efficacy and Safety of Dulaglutide Monotherapy Compared to Glimepiride in Oral Antihyperglycemic Medication-Naïve Chinese patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN1
Yi Ming Li
Li Hui Zhang
Xue Jun Li
Bin Zhang
Jia Ning Hou
Nan Wei Tong
Diabetes Therapy, 2020, 11 : 1077 - 1090
[50] A Target HbA1c Between 7 and 7.7% Reduces Microvascular and Macrovascular Events in T2D Regardless of Duration of Diabetes: a Meta-Analysis of Randomized Controlled Trials
Binayak Sinha
Samit Ghosal
Diabetes Therapy, 2021, 12 : 1661 - 1676

← 1 2 3 4 5 →